Why the study?
Does disopyramide improve dynamic outflow obstruction in a patient with hypertrophic cardiomyopathy and acute myocarditis?
Does disopyramide improve dynamic outflow obstruction in a patient with hypertrophic cardiomyopathy and acute myocarditis?
Disopyramide can effectively relieve dynamic LV outflow obstruction and pulmonary edema in patients with hypertrophic cardiomyopathy complicated by acute myocarditis.
Answers are grounded in this paper and cite their sources.
May support acute disopyramide for LVOTO relief in HCM-myocarditis; hypothesis-generating, needs prospective trials before practice change.
A 65-year-old woman was admitted to the coronary care unit because of acute pulmonary edema. Immediate 2-dimensional and Doppler echocardiograms revealed extensive left ventricular wall motion abnormalities and left ventricular hypertrophy with extreme outflow obstruction. Although an ECG showed ST-segment elevation in the anterolateral leads, a coronary arteriogram revealed normal epicardial arteries. Heart failure was relieved after diminishing the dynamic outflow obstruction with disopyramide administration. An endomyocardial biopsy from the right ventricle on the 8th hospital day showed borderline myocarditis. Wall motion abnormalities gradually normalized within 2 weeks. It is speculated that her pulmonary edema would not have been relieved so readily without the immediate reduction in ventricular afterload by disopyramide. These clinical changes over time were observed with serial echo-Doppler examinations.
No takes yet. Share an insight, caveat, or question.
Sakai et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: